<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053363</url>
  </required_header>
  <id_info>
    <org_study_id>201312010</org_study_id>
    <nct_id>NCT02053363</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Dosing in Adult Spinal Deformity Surgery</brief_title>
  <official_title>Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AOSpine North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate two dosing protocols for tranexamic acid (TXA), an
      anti-fibrinolytic used to decrease blood loss in adult patients undergoing complex,
      reconstructive spinal fusion surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consent is obtained and the patient is enrolled in the trial, patients will be assigned
      de-identified, unique identification (ID) numbers. Randomization of these IDs to either low
      or high dose TXA will occur via a computer generated random assignment. Given the variations
      that may exist in surgical technique (e.g. performance of osteotomies), stratified
      randomization will be performed by attending surgeon. Based upon the randomization, the
      pharmacy will prepare TXA for one of two intravenous dosing protocols:

        1. Low Dose (Standard of Care/Control): Loading Dose 10mg/kg given over 15 minutes,
           followed by 1mg/kg/hr via continuous infusion

        2. High Dose (Study Group): Loading Dose 50mg/kg given over 15 minutes, followed by
           5mg/kg/hr via continuous infusion.

      The surgeon, anesthesia team, and operating room staff will be blind to the concentration of
      TXA in the medications received. Treatments may be &quot;unblinded&quot; at the discretion of the
      surgeon and anesthesiologist, in cases of extreme blood loss. If additional
      anti-fibrinolytics are given, the change in dose will be recorded.

      Post-operative care will be the same as any other patient and data collection will be
      information contained in the patient's medical record that is part of routine, standard of
      care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay, an expected average of 1 week.</time_frame>
    <description>To compare the estimated blood loss in patients undergoing complex, reconstructive, spinal fusion surgeries receiving one of two dosing protocols for the anti-fibrinolytic, TXA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Transfusions</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay, an expected average of 1 week.</time_frame>
    <description>To compare the mean number of packed red blood cell (PRBC) transfusions given to the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>90 days</time_frame>
    <description>To compare the rates of intraoperative complications and 90 day complications observed in the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adult Spinal Deformity</condition>
  <arm_group>
    <arm_group_label>High Dose/Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care/Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (Cyklokapron)</intervention_name>
    <arm_group_label>High Dose/Study Group</arm_group_label>
    <arm_group_label>Standard of Care/Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (ages 18-75) scheduled to undergo long segment (greater than 8 motion
             segments) posterior spinal fusion with instrumentation (PSF) for adult scoliosis

        Exclusion Criteria:

          -  Patients with acquired defective color vision

          -  Subarachnoid hemorrhage

          -  Active intravascular clotting

          -  Hypersensitivity to tranexamic acid or any of the ingredients

          -  Patients who pre-donate autologous blood for intra- or post-operative use (Directed
             donor units are acceptable)

          -  History of suspected blood disorders or abnormal coagulation laboratory results

          -  Current anticoagulation therapy that cannot be interrupted

          -  History of deep vein thrombosis (DVT)

          -  Impaired renal function or creatinine clearance &lt;60 ml/min

          -  Pregnancy or women who are lactating/breastfeeding

          -  Women on hormonal contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P. Kelly, MD, MSCI(p)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael P Kelly, MD, MSCI(p)</last_name>
    <phone>314-747-2535</phone>
    <email>kellymi@wudosis.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elfaridah P. Frazier, PhD</last_name>
      <phone>314-747-2574</phone>
      <email>fraziera@wudosis.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Michael P. Kelly, MD, MSCI(p)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence Lenke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Bridwell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baldus CR, Bridwell KH, Lenke LG, Okubadejo GO. Can we safely reduce blood loss during lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A comparative study with controls. Spine (Phila Pa 1976). 2010 Jan 15;35(2):235-9. doi: 10.1097/BRS.0b013e3181c86cb9.</citation>
    <PMID>20081519</PMID>
  </reference>
  <reference>
    <citation>Neilipovitz DT. Tranexamic acid for major spinal surgery. Eur Spine J. 2004 Oct;13 Suppl 1:S62-5. Epub 2004 May 4. Review.</citation>
    <PMID>15127250</PMID>
  </reference>
  <reference>
    <citation>Okubadejo GO, Bridwell KH, Lenke LG, Buchowski JM, Fang DD, Baldus CR, Nielsen CH, Lee CC. Aprotinin may decrease blood loss in complex adult spinal deformity surgery, but it may also increase the risk of acute renal failure. Spine (Phila Pa 1976). 2007 Sep 15;32(20):2265-71.</citation>
    <PMID>17873821</PMID>
  </reference>
  <reference>
    <citation>Berenholtz SM, Pham JC, Garrett-Mayer E, Atchison CW, Kostuik JP, Cohen DB, Nundy S, Dorman T, Ness PM, Klag MJ, Pronovost PJ, Kebaish KM. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine (Phila Pa 1976). 2009 Sep 1;34(19):2096-103. doi: 10.1097/BRS.0b013e3181b1fab2.</citation>
    <PMID>19730217</PMID>
  </reference>
  <reference>
    <citation>Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine (Phila Pa 1976). 2008 Nov 15;33(24):2577-80. doi: 10.1097/BRS.0b013e318188b9c5.</citation>
    <PMID>19011538</PMID>
  </reference>
  <reference>
    <citation>Gill JB, Chin Y, Levin A, Feng D. The use of antifibrinolytic agents in spine surgery. A meta-analysis. J Bone Joint Surg Am. 2008 Nov;90(11):2399-407. doi: 10.2106/JBJS.G.01179. Review.</citation>
    <PMID>18978408</PMID>
  </reference>
  <reference>
    <citation>Neilipovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WM. A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesth Analg. 2001 Jul;93(1):82-7.</citation>
    <PMID>11429344</PMID>
  </reference>
  <reference>
    <citation>Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology. 2005 Apr;102(4):727-32.</citation>
    <PMID>15791100</PMID>
  </reference>
  <reference>
    <citation>Shapiro F, Zurakowski D, Sethna NF. Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for duchenne muscular dystrophy scoliosis. Spine (Phila Pa 1976). 2007 Sep 15;32(20):2278-83.</citation>
    <PMID>17873823</PMID>
  </reference>
  <reference>
    <citation>Grant JA, Howard J, Luntley J, Harder J, Aleissa S, Parsons D. Perioperative blood transfusion requirements in pediatric scoliosis surgery: the efficacy of tranexamic acid. J Pediatr Orthop. 2009 Apr-May;29(3):300-4. doi: 10.1097/BPO.0b013e31819a85de.</citation>
    <PMID>19305284</PMID>
  </reference>
  <reference>
    <citation>Goobie SM, Meier PM, Pereira LM, McGowan FX, Prescilla RP, Scharp LA, Rogers GF, Proctor MR, Meara JG, Soriano SG, Zurakowski D, Sethna NF. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology. 2011 Apr;114(4):862-71. doi: 10.1097/ALN.0b013e318210fd8f.</citation>
    <PMID>21364458</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Michael Kelly</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid, reconstructive spine surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

